Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose

被引:24
作者
Birmingham, MC
Guarino, R
Heller, A
Wilton, JH
Shah, A
Hejmanowski, L
Nix, DE
Schentag, JJ
机构
[1] Millard Fillmore Hlth Syst, Clin Pharmacokinet Lab, Buffalo, NY 14209 USA
[2] Bayer Corp, Div Pharmaceut, W Haven, CT USA
关键词
D O I
10.1093/jac/43.suppl_1.43
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Intravenous ciprofloxacin is frequently prescribed for the treatment of infections due to nosocomially acquired Gram-negative organisms, including those originating in the respiratory tract. In this study, the concentrations of ciprofloxacin In serum and lung tissue were determined by HPLC in patients undergoing lung surgery. A total of 22 patients scheduled for lung surgery received a single 400 mg iv dose of ciprofloxacin administered as a 1 h infusion. A specimen of healthy lung tissue was obtained from resected lung from 18 of the patients for analysis of ciprofloxacin concentration during the following time intervals after infusion tone sample/patient): 0-2, 2-4, 4-8 and 8-12 h. Corresponding mean serum and tissue concentrations were 2.37 mg/L and 3.84 mg/kg (0-2 h), 1.18 mg/L and 1.92 mg/kg (2-4 h), 0.69 mg/L and 1.77 mg/kg (4-8 h), and 0.13 mg/L and 0.67 mg/kg (8-12 h). Ciprofloxacin distributed rapidly to lung tissue, as seen by the high concentrations in the lung tissue as early as 2 h after infusion. Concentrations in lung tissue were generally higher than those in serum (tissue:serum ratios ranged from 1.7 to 7.1). The mean tissue concentrations found in this study remained above the MIC for most susceptible organisms.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 20 条
[1]  
BACRACHEVA N, 1991, INT J CLIN PHARM TH, V29, P352
[2]   PULMONARY DISPOSITION OF ANTIMICROBIAL AGENTS - METHODOLOGICAL CONSIDERATIONS [J].
BALDWIN, DR ;
HONEYBOURNE, D ;
WISE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) :1171-1175
[3]   COMPARATIVE BRONCHOALVEOLAR CONCENTRATIONS OF CIPROFLOXACIN AND LOMEFLOXACIN FOLLOWING ORAL-ADMINISTRATION [J].
BALDWIN, DR ;
WISE, R ;
ANDREWS, JM ;
GILL, M ;
HONEYBOURNE, D .
RESPIRATORY MEDICINE, 1993, 87 (08) :595-601
[4]  
BERGER BG, 1986, CURRENT SELECTED RES, V1, P97
[5]  
CARUSO E, 1988, 6 MED C CHEM TAOR IT
[6]   AZITHROMYCIN (CP-62,993) IN ACUTE EXACERBATIONS OF CHRONIC-BRONCHITIS - AN OPEN CLINICAL, MICROBIOLOGICAL AND PHARMACOKINETIC STUDY [J].
DAVIES, BI ;
MAESEN, FPV ;
GUBBELMANS, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (05) :743-751
[7]   Ciprofloxacin - An updated review of its pharmacology, therapeutic efficacy and tolerability [J].
Davis, R ;
Markham, A ;
Balfour, JA .
DRUGS, 1996, 51 (06) :1019-1074
[8]   TREATMENT OF SEVERE PNEUMONIA IN HOSPITALIZED-PATIENTS - RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING INTRAVENOUS CIPROFLOXACIN WITH IMIPENEM-CILASTATIN [J].
FINK, MP ;
SNYDMAN, DR ;
NIEDERMAN, MS ;
LEEPER, KV ;
JOHNSON, RH ;
HEARD, SO ;
WUNDERINK, RG ;
CALDWELL, JW ;
SCHENTAG, JJ ;
SIAMI, GA ;
ZAMECK, RL ;
HAVERSTOCK, DC ;
REINHART, HH ;
ECHOLS, RM ;
HELSMOORTEL, C ;
SOJASTRZEPA, D ;
SCHWAITZBERG, S ;
BAREFOOT, L ;
FEIN, AM ;
FEINSILVER, SH ;
ILOWITE, JS ;
CLARE, N ;
SCHULMAN, D ;
JONES, CB ;
GRIFFIN, RI ;
WROBEL, CW ;
BALLOW, CH ;
AMSDEN, G ;
MITCHELL, P ;
BESS, T ;
WILKINS, W ;
BROWN, RB ;
MCGEE, W ;
SAFFORD, MJ ;
LEVINE, DP ;
LERNER, SA ;
KRUSE, JA ;
BANDER, JJ ;
MCNEIL, P ;
MUNKARAH, M ;
SUMMER, WR ;
DEBOISBLANC, B ;
LEVISON, ME ;
KORZENIOWSKI, O ;
SIGLER, A ;
BALDASSARRE, J ;
WALSH, P ;
SAMEL, C ;
SESSLER, CN ;
POLK, RE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (03) :547-557
[9]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[10]  
FORST H, 1989, ARZNEIMITTEL-FORSCH, V39-1, P618